Literature DB >> 1314406

Lipopolysaccharide suppresses cytokine release from coxsackie virus-infected human monocytes.

A Henke1, H P Spengler, A Stelzner, M Nain, D Gemsa.   

Abstract

Infections by coxsackie virus B3 (CVB3) have been reported to be associated with an enhanced influx of mononuclear leukocytes into afflicted tissue. Current evidence indicates that monocytes/macrophages are specifically involved in CVB3-induced myocarditis by maintaining a chronic inflammatory response. To examine susceptibility and reactivity to CVB3, freshly isolated human monocytes were exposed to various virus doses (0.1-10 MOI) in the presence or absence of macrophage-activating lipopolysaccharide (LPS). CVB3 infection alone induced an activation of monocytes as evidenced by enhanced adherence, release of cytokines and secretion of prostaglandin E2 (PGE2). Simultaneous addition of LPS almost entirely suppressed LPS-specific production of tumour necrosis factor alpha (TNF alpha) and PGE2, partially inhibited release of interleukin 1 beta (IL 1 beta) and did not affect interleukin 6 (IL6) synthesis of CVB3-infected monocytes. These data show that CVB3 activates monocytes to cytokine production but renders them unreactive to further activating stimuli. Further studies should determine the extent to which continuous cytokine release from persistently CVB3-infected monocytes, and their apparent unresponsiveness to other stimuli, contribute to chronic myocarditis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314406     DOI: 10.1016/0923-2494(92)80081-u

Source DB:  PubMed          Journal:  Res Immunol        ISSN: 0923-2494


  9 in total

1.  Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density.

Authors:  S D Carson; J T Hobbs; S M Tracy; N M Chapman
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives.

Authors:  J B Marriott; J H Goldman; P J Keeling; M K Baig; A G Dalgleish; W J McKenna
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

3.  Nitric oxide inhibits viral replication in murine myocarditis.

Authors:  C J Lowenstein; S L Hill; A Lafond-Walker; J Wu; G Allen; M Landavere; N R Rose; A Herskowitz
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression.

Authors:  Neelam Sharma-Walia; Hari Raghu; Sathish Sadagopan; Ramu Sivakumar; Mohanan Valiya Veettil; Pramod P Naranatt; Marilyn M Smith; Bala Chandran
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication.

Authors:  M Huber; K A Watson; H C Selinka; C M Carthy; K Klingel; B M McManus; R Kandolf
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1.

Authors:  Nancy Dumais; Marie-Eve Paré; Simon Mercier; Salim Bounou; Susan J Marriot; Benoit Barbeau; Michel J Tremblay
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3-Induced Myocarditis.

Authors:  Kapka Miteva; Kathleen Pappritz; Muhammad El-Shafeey; Fengquan Dong; Jochen Ringe; Carsten Tschöpe; Sophie Van Linthout
Journal:  Stem Cells Transl Med       Date:  2017-01-03       Impact factor: 6.940

Review 8.  Prostaglandin E2 As a Modulator of Viral Infections.

Authors:  Willem J Sander; Hester G O'Neill; Carolina H Pohl
Journal:  Front Physiol       Date:  2017-02-14       Impact factor: 4.566

Review 9.  Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-04-06       Impact factor: 7.012

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.